Startup valuation is part science, part art. Early-stage companies rely on perceived market potential and the founding team's credibility, while later-stage companies use concrete metrics like cash flow and assets. Expect less precision at the beginning.
I would say that, you know, valuation is definitely part science and part art. There's a, you know, the science part of it that comes later when you have actual things that you can value and say, you know, based on cash flow, based on assets, based on IP. But when you're in that earlier stage, you know, really it's just based on what you view the market potential is and your capability to, you know, capture some of that market potential and, you know, being realistic and not necessarily, you know, pinpointing one value.
